Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Capital Expenditures (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Capital Expenditures for 9 consecutive years, with -$31000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures changed N/A year-over-year to -$31000.0, compared with a TTM value of $835000.0 through Dec 2025, changed N/A, and an annual FY2025 reading of $835000.0, changed N/A over the prior year.
  • Capital Expenditures was -$31000.0 for Q4 2025 at Zevra Therapeutics, down from $554000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $554000.0 in Q3 2025 and bottomed at -$31000.0 in Q4 2025.
  • Average Capital Expenditures over 4 years is $88400.0, with a median of $29000.0 recorded in 2023.
  • The sharpest move saw Capital Expenditures soared 666.67% in 2021, then crashed 55.56% in 2022.
  • Year by year, Capital Expenditures stood at $17000.0 in 2021, then skyrocketed by 100.0% to $34000.0 in 2022, then surged by 111.76% to $72000.0 in 2023, then plummeted by 143.06% to -$31000.0 in 2025.
  • Business Quant data shows Capital Expenditures for ZVRA at -$31000.0 in Q4 2025, $554000.0 in Q3 2025, and $213000.0 in Q2 2025.